Targeting histone lysine demethylases - Progress, challenges, and the future

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1839, Issue 12, 2014, Pages 1416-1432

  Thinnes, Cyrille C ^a   England, Katherine S ^a   Kawamura, Akane ^a   Chowdhury, Rasheduzzaman ^a   Schofield, Christopher J ^a   Hopkinson, Richard J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Demethylase; Epigenetics; Histone; Inhibition; Lysine; Methylation

Indexed keywords

ENZYME INHIBITOR; HISTONE DEMETHYLASE; PROTEIN BINDING;

ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES;

ANIMALS; ENZYME INHIBITORS; HISTONE DEMETHYLASES; HUMANS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN BINDING;

EID: 84914118716     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2014.05.009     Document Type: Review

References (157)

1. Berdasco M., Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev. Cell 2010, 19:698-711.
2. Suganuma T., Workman J.L. Signals and combinatorial functions of histone modifications. Annu. Rev. Biochem. 2011, 80:473-499.
3. Zentner G.E., Henikoff S. Regulation of nucleosome dynamics by histone modifications. Nat. Struct. Mol. Biol. 2013, 20:259-266.
4. Greer E.L., Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat. Rev. Genet. 2012, 13:343-357.
5. Portela A., Esteller M. Epigenetic modifications and human disease. Nat. Biotechnol. 2010, 28:1057-1068.
6. Waldmann T., Schneider R. Targeting histone modifications-epigenetics in cancer. Curr. Opin. Cell Biol. 2013, 25:184-189.
7. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
8. Rotili D., Mai A. Targeting histone demethylases: a new avenue for the fight against cancer. Gene Cancer 2011, 2:663-679.
9. Gravina G.L., Festuccia C., Marampon F., Popov V.M., Pestell R.G., Zani B.M., Tombolini V. Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol. Cancer 2010, 9.
10. Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S., McKinney K., Tempst P., Prives C., Gamblin S.J., Barlev N.A., Reinberg D. Regulation of p53 activity through lysine methylation. Nature 2004, 432:353-360.
11. Levy D., Kuo A.J., Chang Y., Schaefer U., Kitson C., Cheung P., Espejo A., Zee B.M., Liu C.L., Tangsombatvisit S., Tennen R.I., Kuo A.Y., Tanjing S., Cheung R., Chua K.F., Utz P.J., Shi X., Prinjha R.K., Lee K., Garcia B.A., Bedford M.T., Tarakhovsky A., Cheng X., Gozani O. Lysine methylation of the NF-[kappa]B subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-[kappa]B signaling. Nat. Immunol. 2011, 12:29-36.
12. Ea C.-K., Baltimore D. Regulation of NF-κB activity through lysine monomethylation of p65. Proc. Natl. Acad. Sci. 2009, 106:18972-18977.
13. Barski A., Cuddapah S., Cui K., Roh T.Y., Schones D.E., Wang Z., Wei G., Chepelev I., Zhao K. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129:823-837.
14. Khoury G.A., Baliban R.C., Floudas C.A. Proteome-wide post-translational modification statistics: frequency analysis and curation of the Swiss-Prot database. Sci. Rep. 2011, 1.
15. Walsh C.T., Garneau-Tsodikova S., Gatto G.J. Protein posttranslational modifications: the chemistry of proteome diversifications. Angew. Chem. 2005, 44:7342-7372.
16. Albert M., Helin K. Histone methyltransferases in cancer. Semin. Cell Dev. Biol. 2010, 21:209-220.
17. Bernt K.M., Zhu N., Sinha A.U., Vempati S., Faber J., Krivtsov A.V., Feng Z., Punt N., Daigle A., Bullinger L., Pollock R.M., Richon V.M., Kung A.L., Armstrong S.A. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78.
18. Okada Y., Feng Q., Lin Y., Jiang Q., Li Y., Coffield V.M., Su L., Xu G., Zhang Y. hDOT1L links histone methylation to leukemogenesis. Cell 2005, 121:167-178.
19. Margueron R., Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011, 469:343-349.
20. Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003, 22:5323-5335.
21. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., Ghosh D., Pienta K.J., Sewalt R.G., Otte A.P., Rubin M.A., Chinnaiyan A.M. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629.
22. Daigle S.R., Olhava E.J., Therkelsen C.A., Basavapathruni A., Jin L., Boriack-Sjodin P.A., Allain C.J., Klaus C.R., Raimondi A., Scott M.P., Waters N.J., Chesworth R., Moyer M.P., Copeland R.A., Richon V.M., Pollock R.M. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013, 122:1017-1025.
23. http://www.epizyme.com.
24. McCabe M.T., Ott H.M., Ganji G., Korenchuk S., Thompson C., Van Aller G.S., Liu Y., Graves A.P., Iii A.D.P., Diaz E., LaFrance L.V., Mellinger M., Duquenne C., Tian X., Kruger R.G., McHugh C.F., Brandt M., Miller W.H., Dhanak D., Verma S.K., Tummino P.J., Creasy C.L. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492:108-112.
25. Dawson M.A., Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27.
26. Walport L.J., Hopkinson R.J., Schofield C.J. Mechanisms of human histone and nucleic acid demethylases. Curr. Opin. Chem. Biol. 2012, 16:525-534.
27. Kooistra S.M., Helin K. Molecular mechanisms and potential functions of histone demethylases. Nat. Rev. Mol. Cell Biol. 2012, 13:297-311.
28. Wang Y., Wysocka J., Sayegh J., Lee Y.H., Perlin J.R., Leonelli L., Sonbuchner L.S., McDonald C.H., Cook R.G., Dou Y., Roeder R.G., Clarke S., Stallcup M.R., Allis C.D., Coonrod S.A. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 2004, 306:279-283.
29. Cuthbert G.L., Daujat S., Snowden A.W., Erdjument-Bromage H., Hagiwara T., Yamada M., Schneider R., Gregory P.D., Tempst P., Bannister A.J., Kouzarides T. Histone deimination antagonizes arginine methylation. Cell 2004, 118:545-553.
30. Chang B., Chen Y., Zhao Y., Bruick R.K. JMJD6 is a histone arginine demethylase. Science 2007, 318:444-447.
31. Liu W., Ma Q., Wong K., Li W., Ohgi K., Zhang J., Aggarwal A.K., Rosenfeld M.G. Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release. Cell 2013, 155:1581-1595.
32. Webby C.J., Wolf A., Gromak N., Dreger M., Kramer H., Kessler B., Nielsen M.L., Schmitz C., Butler D.S., Yates J.R., Delahunty C.M., Hahn P., Lengeling A., Mann M., Proudfoot N.J., Schofield C.J., Bottger A. Jmjd6 catalyses lysyl-hydroxylation of U2AF65, a protein associated with RNA splicing. Science 2009, 325:90-93.
33. Mantri M., Loik N.D., Hamed R.B., Claridge T.D., McCullagh J.S., Schofield C.J. The 2-oxoglutarate-dependent oxygenase JMJD6 catalyses oxidation of lysine residues to give 5S-hydroxylysine residues. Chembiochem 2011, 12:531-534.
34. Shi Y. Histone lysine demethylases: emerging roles in development, physiology and disease, Nature reviews. Genetics 2007, 8:829-833.
35. Hayami S., Kelly J.D., Cho H.-S., Yoshimatsu M., Unoki M., Tsunoda T., Field H.I., Neal D.E., Yamaue H., Ponder B.A.J., Nakamura Y., Hamamoto R. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 2011, 128:574-586.
36. Harris W.J., Huang X., Lynch J.T., Spencer G.J., Hitchin J.R., Li Y., Ciceri F., Blaser J.G., Greystoke B.F., Jordan A.M., Miller C.J., Ogilvie D.J., Somervaille T.C.P. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012, 21:473-487.
37. Hoffmann I., Roatsch M., Schmitt M.L., Carlino L., Pippel M., Sippl W., Jung M. The role of histone demethylases in cancer therapy. Mol. Oncol. 2012, 6:683-703.
38. Forneris F., Binda C., Adamo A., Battaglioli E., Mattevi A. Structural basis of LSD1-CoREST selectivity in histone H3 recognition. J. Biol. Chem. 2007, 282:20070-20074.
39. Metzger E., Wissmann M., Yin N., Muller J.M., Schneider R., Peters A.H., Gunther T., Buettner R., Schule R. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005, 437:436-439.
40. Klose R.J., Kallin E.M., Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat. Rev. Genet. 2006, 7:715-727.
41. Tahiliani M., Mei P., Fang R., Leonor T., Rutenberg M., Shimizu F., Li J., Rao A., Shi Y. The histone H3K4 demethylase SMCX links REST target genes to X-linked mental retardation. Nature 2007, 447:601-605.
42. Castermans D., Vermeesch J.R., Fryns J.-P., Steyaert J.G., Van de Ven W.J.M., Creemers J.W.M., Devriendt K. Identification and characterization of the TRIP8 and REEP3 genes on chromosome 10q21.3 as novel candidate genes for autism. Eur. J. Hum. Genet. 2007, 15:422-431.
43. Laumonnier F., Holbert S., Ronce N., Faravelli F., Lenzner S., Schwartz C.E., Lespinasse J., Van Esch H., Lacombe D., Goizet C., Phan-Dinh Tuy F., van Bokhoven H., Fryns J.-P., Chelly J., Ropers H.-H., Moraine C., Hamel B.C.J., Briault S. Mutations in PHF8 are associated with X linked mental retardation and cleft lip/cleft palate. J. Med. Genet. 2005, 42:780-786.
44. Qiu J., Shi G., Jia Y., Li J., Wu M., Li J., Dong S., Wong J. The X-linked mental retardation gene PHF8 is a histone demethylase involved in neuronal differentiation. Cell Res. 2010, 20:908-918.
45. Thalhammer A., Aik W., Bagg E.A.L., Schofield C.J. The potential of 2-oxoglutarate oxygenases acting on nucleic acids as therapeutic targets. Drug Discov. Today 2012, 9:e91-e100.
46. Tsukada Y., Fang J., Erdjument-Bromage H., Warren M.E., Borchers C.H., Tempst P., Zhang Y. Histone demethylation by a family of JmjC domain-containing proteins. Nature 2006, 439:811-816.
47. Hopkinson R.J., Hamed R.B., Rose N.R., Claridge T.D.W., Schofield C.J. Monitoring the activity of 2-oxoglutarate dependent histone demethylases by NMR spectroscopy: direct observation of formaldehyde. Chembiochem 2010, 11:506-510.
48. Shi Y., Lan F., Matson C., Mulligan P., Whetstine J.R., Cole P.A., Casero R.A., Shi Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119:941-953.
49. Willmann D., Lim S., Wetzel S., Metzger E., Jandausch A., Wilk W., Jung M., Forne I., Imhof A., Janzer A., Kirfel J., Waldmann H., Schule R., Buettner R. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int. J. Cancer 2012, 131:2704-2709.
50. Loenarz C., Schofield C.J. Expanding chemical biology of 2-oxoglutarate oxygenases. Nat. Chem. Biol. 2008, 4:152-156.
51. Shih J.C., Chen K., Ridd M.J. Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci. 1999, 22:197-217.
52. Rose N.R., Woon E.C.Y., Kingham G.L., King O.N.F., Mecinovic J., Clifton I.J., Ng S.S., Talib-Hardy J., Oppermann U., McDonough M.A., Schofield C.J. Selective inhibitors of the JMJD2 histone demethylases: combined nondenaturing mass spectrometric screening and crystallographic approaches. J. Med. Chem. 2010, 53:1810-1818.
53. Hopkinson R.J., Tumber A., Yapp C., Chowdhury R., Aik W., Che K.H., Li X.S., Kristensen J.B.L., King O.N.F., Chan M.C., Yeoh K.K., Choi H., Walport L.J., Thinnes C.C., Bush J.T., Lejeune C., Rydzik A.M., Rose N.R., Bagg E.A., McDonough M.A., Krojer T.J., Yue W.W., Ng S.S., Olsen L., Brennan P.E., Oppermann U., Muller S., Klose R.J., Ratcliffe P.J., Schofield C.J., Kawamura A. 5-Carboxy-8-hydroxyquinoline is a broad spectrum 2-oxoglutarate oxygenase inhibitor which causes iron translocation. Chem. Sci. 2013, 4:3110-3117.
54. Lee M.G., Wynder C., Schmidt D.M., McCafferty D.G., Shiekhattar R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem. Biol. 2006, 13:563-567.
55. Schmidt D.M., McCafferty D.G. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 2007, 46:4408-4416.
56. Forneris F., Binda C., Vanoni M.A., Battaglioli E., Mattevi A. Human histone demethylase LSD1 reads the histone code. J. Biol. Chem. 2005, 280:41360-41365.
57. Culhane J.C., Wang D., Yen P.M., Cole P.A. Comparative analysis of small molecules and histone substrate analogues as LSD1 lysine demethylase inhibitors. J. Am. Chem. Soc. 2010, 132:3164-3176.
58. Hellerman L., Erwin V.G. Mitochondrial monoamine oxidase. II. Action of various inhibitors for the bovine kidney enzyme. Catalytic mechanism. J. Biol. Chem. 1968, 243:5234-5243.
59. Binda C., Li M., Hubalek F., Restelli N., Edmondson D.E., Mattevi A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:9750-9755.
60. Patek D.R., Hellerman L. Mitochondrial monoamine oxidase. Mechanism of inhibition by phenylhydrazine and by aralkylhydrazines. Role of enzymatic oxidation. J. Biol. Chem. 1974, 249:2373-2380.
61. Binda C., Valente S., Romanenghi M., Pilotto S., Cirilli R., Karytinos A., Ciossani G., Botrugno O.A., Forneris F., Tardugno M., Edmondson D.E., Minucci S., Mattevi A., Mai A. Biochemical, structural, and biological evaluation of tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and LSD2. J. Am. Chem. Soc. 2010, 132:6827-6833.
62. Yang M., Culhane J.C., Szewczuk L.M., Jalili P., Ball H.L., Machius M., Cole P.A., Yu H. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine. Biochemistry 2007, 46:8058-8065.
63. Mimasu S., Sengoku T., Fukuzawa S., Umehara T., Yokoyama S. Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 A. Biochem. Biophys. Res. Commun. 2008, 366:15-22.
64. Gooden D.M., Schmidt D.M., Pollock J.A., Kabadi A.M., McCafferty D.G. Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B. Bioorg. Med. Chem. Lett. 2008, 18:3047-3051.
65. Ueda R., Suzuki T., Mino K., Tsumoto H., Nakagawa H., Hasegawa M., Sasaki R., Mizukami T., Miyata N. Identification of cell-active lysine specific demethylase 1-selective inhibitors. J. Am. Chem. Soc. 2009, 131:17536-17537.
66. Mimasu S., Umezawa N., Sato S., Higuchi T., Umehara T., Yokoyama S. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1. Biochemistry 2010, 49:6494-6503.
67. Neelamegam R., Ricq E.L., Malvaez M., Patnaik D., Norton S., Carlin S.M., Hill I.T., Wood M.A., Haggarty S.J., Hooker J.M. Brain-penetrant LSD1 inhibitors can block memory consolidation. ACS Chem. Neurosci. 2012, 3:120-128.
68. Oryzen Genomics S.A. Phenylcyclopropylamine Derivatives and their Medical Use 2010.
69. T.C.S.F.E.C.d.L. Maes, M.C.S.F.E.C.d.L. Martinell Pedemonte, J.C.C.S.F.E.C.d.L. Castro-Palomino Laria, LYSINE DEMETHYLASE INHIBITORS SUCH AS CYCLYLCYLOPROPAMINE DERIVATIVES FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES OR CONDITIONS, in: S.A.C.S.F.E.C.d.L. Oryzon Genomics (Ed.), vol. EP2012/059377, WO, 2012.
70. S.V.S.M.I.O. Minucci, A.V.J.F.I.R. Mai, A.V.M.I.P. Mattevi, TRANYLCYPROMINE DERIVATIVES AS INHIBITORS OF HISTONE DEMETHYLASE LSD1 AND/OR LSD2, in: P.A.M.I.R. UniversitÀ Degli Studi Di Roma "La Sapienza, V.F.I.M. Fondazione Ieo, C.S.N.I.P. UniversitÀ Degli Studi Di Pavia, V.F.d.P.I.M. UniversitÀ Degli Studi Di Milano (Eds.), vol. EP2011/055990, WO, 2011.
71. Harris W.J., Huang X., Lynch J.T., Spencer G.J., Hitchin J.R., Li Y., Ciceri F., Blaser J.G., Greystoke B.F., Jordan A.M., Miller C.J., Ogilvie D.J., Somervaille T.C. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012, 21:473-487.
72. Maes T., Tirapu I., Mascaro C., Ortega A., Estiarte A., Valls N., Castro-Palomino J., Buesa Arjol C., Kurz G. Preclinical characterization of a potent and selective inhibitor of the histone demethylase KDM1A for MLL leukemia. ASCO Meeting Abstracts 2013, 31:e13543.
73. Culhane J.C., Szewczuk L.M., Liu X., Da G., Marmorstein R., Cole P.A. A mechanism-based inactivator for histone demethylase LSD1. J. Am. Chem. Soc. 2006, 128:4536-4537.
74. Szewczuk L.M., Culhane J.C., Yang M., Majumdar A., Yu H., Cole P.A. Mechanistic analysis of a suicide inactivator of histone demethylase LSD1. Biochemistry 2007, 46:6892-6902.
75. Federico R., Leone L., Botta M., Binda C., Angelini R., Venturini G., Ascenzi P. Inhibition of pig liver and Zea mays L. polyamine oxidase: a comparative study. J. Enzym Inhib. 2001, 16:147-155.
76. Bianchi M., Polticelli F., Ascenzi P., Botta M., Federico R., Mariottini P., Cona A. Inhibition of polyamine and spermine oxidases by polyamine analogues. FEBS J. 2006, 273:1115-1123.
77. Huang Y., Greene E., Murray Stewart T., Goodwin A.C., Baylin S.B., Woster P.M., Casero R.A. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc. Natl. Acad. Sci. 2007, 104:8023-8028.
78. Huang Y., Stewart T.M., Wu Y., Baylin S.B., Marton L.J., Perkins B., Jones R.J., Woster P.M., Casero R.A. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin. Cancer Res. 2009, 15:7217-7228.
79. Sharma S.K., Wu Y., Steinbergs N., Crowley M.L., Hanson A.S., Casero R.A., Woster P.M. (Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators. J. Med. Chem. 2010, 53:5197-5212.
80. H.O.B.W.L.V.N.V. Zhang, T.S.U.T.X.N.D.S.G. Ye, J.S.U.T.X.N.D.S.G. Quan, J.S.U.T.X.N.D.S.G. Wang, HISTONE DEMETHYLASE INHIBITORS AND USES THEREOF FOR TREATMENT O F CANCER, in: O.B.W.L.V.N.V. Nevada Cancer Institute, S.U.T.X.N.D.S.G. Shenzhen Graduate School Of Peking University (Eds.), vol. US2011/061954, WO, 2012.
81. Liu H., Zheng Y., Duan Y., Lu W., Ma J., Yang A., Yang K. Application of amino dithio formic ester compound with triazolyl in preparing medicine taking LSD1 (Lysine Specificity Demethylase 1) as target, in, CN 2013.
82. Hitchin J.R., Blagg J., Burke R., Burns S., Cockerill M.J., Fairweather E.E., Hutton C., Jordan A.M., McAndrew C., Mirza A., Mould D., Thomson G.J., Waddell I., Ogilvie D.J. Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments. Med. Chem. Commun. 2013, 4:1513-1522.
83. Lynch J.T., Cockerill M.J., Hitchin J.R., Wiseman D.H., Somervaille T.C. CD86 expression as a surrogate cellular biomarker for pharmacological inhibition of the histone demethylase lysine-specific demethylase 1. Anal. Biochem. 2013, 442:104-106.
84. Sorna V., Theisen E.R., Stephens B., Warner S.L., Bearss D.J., Vankayalapati H., Sharma S. High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors. J. Med. Chem. 2013, 56:9496-9508.
85. Dhanak D. Drugging the cancer genome. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research 2013.
86. Majamaa K., Sasaki T., Uitto J. Inhibition of prolyl hydroxylation during collagen biosynthesis in human skin fibroblast cultures by ethyl 3,4-dihydroxybenzoate. J. Investig. Dermatol. 1987, 89:405-409.
87. Franklin T.J., Hitchen M. Inhibition of collagen hydroxylation by 2,7,8-trihydroxyanthraquinone in embryonic-chick tendon cells. Biochem. J. 1989, 261:127-130.
88. Rose N.R., McDonough M.A., King O.N.F., Kawamura A., Schofield C.J. Inhibition of 2-oxoglutarate dependent oxygenases. Chem. Soc. Rev. 2011, 40:4364-4397.
89. Schofield C.J., Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol. 2004, 5:343-354.
90. Clifton I.J., McDonough M.A., Ehrismann D., Kershaw N.J., Granatino N., Schofield C.J. Structural studies on 2-oxoglutarate oxygenases and related double-stranded β-helix fold proteins. J. Inorg. Biochem. 2006, 100:644-669.
91. McDonough M.A., Loenarz C., Chowdhury R., Clifton I.J., Schofield C.J. Structural studies on human 2-oxoglutarate dependent oxygenases. Curr. Opin. Struct. Biol. 2010, 20:659-672.
92. Aik W., McDonough M.A., Thalhammer A., Chowdhury R., Schofield C.J. Role of the jelly-roll fold in substrate binding by 2-oxoglutarate oxygenases. Curr. Opin. Struct. Biol. 2012, 22:691-700.
93. Kruidenier L., Chung C.-w., Cheng Z., Liddle J., Che K., Joberty G., Bantscheff M., Bountra C., Bridges A., Diallo H., Eberhard D., Hutchinson S., Jones E., Katso R., Leveridge M., Mander P.K., Mosley J., Ramirez-Molina C., Rowland P., Schofield C.J., Sheppard R.J., Smith J.E., Swales C., Tanner R., Thomas P., Tumber A., Drewes G., Oppermann U., Patel D.J., Lee K., Wilson D.M. A selective Jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 2012, 488:404-408.
94. Poppe L., Tegley C.M., Li V., Lewis J., Zondlo J., Yang E., Kurzeja R.J.M., Syed R. Different modes of inhibitor binding to prolyl hydroxylase by combined use of X-ray crystallography and NMR spectroscopy of paramagnetic complexes. J. Am. Chem. Soc. 2009, 131:16654-16655.
95. Bleijlevens B., Shivarattan T., Flashman E., Yang Y., Simpson P.J., Koivisto P., Sedgwick B., Schofield C.J., Matthews S.J. Dynamic states of the DNA repair enzyme AlkB regulate product release. EMBO Rep. 2008, 9:872-877.
96. Opocher G., Schiavi F. Functional consequences of succinate dehydrogenase mutations. Endocr. Pract. 2011, 17:64-71.
97. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., Fantin V.R., Jang H.G., Jin S., Keenan M.C., Marks K.M., Prins R.M., Ward P.S., Yen K.E., Liau L.M., Rabinowitz J.D., Cantley L.C., Thompson C.B., Vander Heiden M.G., Su S.M. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744.
98. Losman J.-A., Looper R.E., Koivunen P., Lee S., Schneider R.K., McMahon C., Cowley G.S., Root D.E., Ebert B.L., Kaelin W.G. (R)-2-Hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013, 339:1621-1625.
99. Zhao S., Lin Y., Xu W., Jiang W., Zha Z., Wang P., Yu W., Li Z., Gong L., Peng Y., Ding J., Lei Q., Guan K.L., Xiong Y. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 2009, 324:261-265.
100. Puistola U., Turpeenniemihujanen T.M., Myllyla R., Kivirikko K.I. Studies on the lysyl hydroxylase reaction. 1. Initial velocity kinetics and related aspects. Biochim. Biophys. Acta 1980, 611:40-50.
101. Myllyla R., Tuderman L., Kivirikko K.I. Mechanism of prolyl hydroxylase reaction. 2. Kinetic-analysis of reaction sequence. Eur. J. Biochem. 1977, 80:349-357.
102. Xiao M., Yang H., Xu W., Ma S., Lin H., Zhu H., Liu L., Liu Y., Yang C., Xu Y., Zhao S., Ye D., Xiong Y., Guan K.L. Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2012, 26:1326-1338.
103. Rose N.R., Ng S.S., Mecinovic J., Lienard B.M.R., Bello S.H., Sun Z., McDonough M.A., Oppermann U., Schofield C.J. Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases. J. Med. Chem. 2008, 51:7053-7056.
104. Chowdhury R., Yeoh K.K., Tian Y.M., Hillringhaus L., Bagg E.A., Rose N.R., Leung I.K., Li X.S., Woon E.C., Yang M., McDonough M.A., King O.N., Clifton I.J., Klose R.J., Claridge T.D., Ratcliffe P.J., Schofield C.J., Kawamura A. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep. 2011, 12:463-469.
105. Xu W., Yang H., Liu Y., Yang Y., Wang P., Kim S.H., Ito S., Yang C., Xiao M.T., Liu L.X., Jiang W.Q., Liu J., Zhang J.Y., Wang B., Frye S., Zhang Y., Xu Y.H., Lei Q.Y., Guan K.L., Zhao S.M., Xiong Y. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell 2011, 19:17-30.
106. Couture J.-F., Collazo E., Ortiz-Tello P.A., Brunzelle J.S., Trievel R.C. Specificity and mechanism of JMJD2A, a trimethyllysine-specific histone demethylase. Nat. Struct. Mol. Biol. 2007, 14:689-695.
107. Price J.C., Barr E.W., Hoffart L.M., Krebs C., Bollinger J.M. Kinetic dissection of the catalytic mechanism of taurine:α-ketoglutarate dioxygenase (TauD) from Escherichia coli†. Biochemistry 2005, 44:8138-8147.
108. Welford R.W., Schlemminger I., McNeill L.A., Hewitson K.S., Schofield C.J. The selectivity and inhibition of AlkB. J. Biol. Chem. 2003, 278:10157-10161.
109. Rydzik A.M., Leung I.K., Kochan G.T., Thalhammer A., Oppermann U., Claridge T.D., Schofield C.J. Development and application of a fluoride-detection-based fluorescence assay for gamma-butyrobetaine hydroxylase. Chembiochem 2012, 13:1559-1563.
110. MacKenzie E.D., Selak M.A., Tennant D.A., Payne L.J., Crosby S., Frederiksen C.M., Watson D.G., Gottlieb E. Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol. Cell. Biol. 2007, 27:3282-3289.
111. Sekirnik R., Rose N.R., Thalhammer A., Seden P.T., Mecinovic J., Schofield C.J. Inhibition of the histone lysine demethylase JMJD2A by ejection of structural Zn(ii). Chem. Commun. 2009, 6376-6378.
112. Woon E.C., Demetriades M., Bagg E.A., Aik W., Krylova S.M., Ma J.H., Chan M., Walport L.J., Wegman D.W., Dack K.N., McDonough M.A., Krylov S.N., Schofield C.J. Dynamic combinatorial mass spectrometry leads to inhibitors of a 2-oxoglutarate-dependent nucleic acid demethylase. J. Med. Chem. 2012, 55:2173-2184.
113. Chen B., Ye F., Yu L., Jia G., Huang X., Zhang X., Peng S., Chen K., Wang M., Gong S., Zhang R., Yin J., Li H., Yang Y., Liu H., Zhang J., Zhang H., Zhang A., Jiang H., Luo C., Yang C.G. Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor. J. Am. Chem. Soc. 2012, 134:17963-17971.
114. Aik W., Demetriades M., Hamdan M.K., Bagg E.A., Yeoh K.K., Lejeune C., Zhang Z., McDonough M.A., Schofield C.J. Structural basis for inhibition of the fat mass and obesity associated protein (FTO). J. Med. Chem. 2013, 56:3680-3688.
115. Cunliffe C.J., Franklin T.J., Hales N.J., Hill G.B. Novel inhibitors of prolyl 4-hydroxylase. 3. Inhibition by the substrate analog N-oxaloglycine and its derivatives. J. Med. Chem. 1992, 35:2652-2658.
116. Mole D.R., Schlemminger I., McNeill L.A., Hewitson K.S., Pugh C.W., Ratcliffe P.J., Schofield C.J. 2-Oxoglutarate analogue inhibitors of hif prolyl hydroxylase. Bioorg. Med. Chem. Lett. 2003, 13:2677-2680.
117. Rankin E.B., Wu C., Khatri R., Wilson T.L.S., Andersen R., Araldi E., Rankin A.L., Yuan J., Kuo C.J., Schipani E., Giaccia A.J. The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell 2012, 149:63-74.
118. Tian Y.M., Yeoh K.K., Lee M.K., Eriksson T., Kessler B.M., Kramer H.B., Edelmann M.J., Willam C., Pugh C.W., Schofield C.J., Ratcliffe P.J. Differential sensitivity of hypoxia inducible factor hydroxylation sites to hypoxia and hydroxylase inhibitors. J. Biol. Chem. 2011, 286:13041-13051.
119. McDonough M.A., McNeill L.A., Tilliet M., Papamicaël C.A., Chen Q.-Y., Banerji B., Hewitson K.S., Schofield C.J. Selective inhibition of factor inhibiting hypoxia-inducible factor. J. Am. Chem. Soc. 2005, 127:7680-7681.
120. Ng S.S., Kavanagh K.L., McDonough M.A., Butler D., Pilka E.S., Lienard B.M.R., Bray J.E., Savitsky P., Gileadi O., von Delft F., Rose N.R., Offer J., Scheinost J.C., Borowski T., Sundstrom M., Schofield C.J., Oppermann U. Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity. Nature 2007, 448:87-91.
121. Hamada S., Kim T.-D., Suzuki T., Itoh Y., Tsumoto H., Nakagawa H., Janknecht R., Miyata N. Synthesis and activity of N-oxalylglycine and its derivatives as Jumonji C-domain-containing histone lysine demethylase inhibitors. Bioorg. Med. Chem. Lett. 2009, 19:2852-2855.
122. Hamada S., Suzuki T., Mino K., Koseki K., Oehme F., Flamme I., Ozasa H., Itoh Y., Ogasawara D., Komaarashi H., Kato A., Tsumoto H., Nakagawa H., Hasegawa M., Sasaki R., Mizukami T., Miyata N. Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of Jumonji domain-containing protein 2 histone demethylase inhibitors. J. Med. Chem. 2010, 53:5629-5638.
123. Rose N.R., Woon E.C.Y., Tumber A., Walport L.J., Chowdhury R., Li X.S., King O.N.F., Lejeune C., Ng S.S., Krojer T., Chan M.C., Rydzik A.M., Hopkinson R.J., Che K.H., Daniel M., Strain-Damerell C., Gileadi C., Kochan G., Leung I.K.H., Dunford J., Yeoh K.K., Ratcliffe P.J., Burgess-Brown N., von Delft F., Muller S., Marsden B., Brennan P.E., McDonough M.A., Oppermann U., Klose R.J., Schofield C.J., Kawamura A. Plant growth regulator daminozide is a selective inhibitor of human KDM2/7 histone demethylases. J. Med. Chem. 2012, 55:6639-6643.
124. Suzuki T., Ozasa H., Itoh Y., Zhan P., Sawada H., Mino K., Walport L., Ohkubo R., Kawamura A., Yonezawa M., Tsukada Y., Tumber A., Nakagawa H., Hasegawa M., Sasaki R., Mizukami T., Schofield C.J., Miyata N. Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity. J. Med. Chem. 2013, 56:7222-7231.
125. Luo X., Liu Y., Kubicek S., Myllyharju J., Tumber A., Ng S., Che K.H., Podoll J., Heightman T.D., Oppermann U., Schreiber S.L., Wang X. A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases. J. Am. Chem. Soc. 2011, 133:9451-9456.
126. Brown R.G.S., Kawaide H., Yang Y.-Y., Rademacher W., Kamiya Y. Daminozide and prohexadione have similar modes of action as inhibitors of the late stages of gibberellin metabolism. Physiol. Plant. 1997, 101:309-313.
127. Mackeen M.M., Kramer H.B., Chang K.-H., Coleman M.L., Hopkinson R.J., Schofield C.J., Kessler B.M. Small-molecule-based inhibition of histone demethylation in cells assessed by quantitative mass spectrometry. J. Proteome Res. 2010, 9:4082-4092.
128. Thalhammer A., Mecinovic J., Loenarz C., Tumber A., Rose N.R., Heightman T.D., Schofield C.J. Inhibition of the histone demethylase JMJD2E by 3-substituted pyridine 2,4-dicarboxylates. Org. Biomol. Chem. 2011, 9:127-135.
129. Barker M.D., Campbell M., Diallo H., Douault C., Humphreys P., Liddle J., Sheppard R.J., Thomas P.J., Wilson D.M. Pyridine-4-carboxylic acids as demethylase enzymes inhibitors and their preparation, in, Glaxo Group Limited, UK 2013, (124pp).
130. Wang L., Chang J., Varghese D., Dellinger M., Kumar S., Best A.M., Ruiz J., Bruick R., Peña-Llopis S., Xu J., Babinski D.J., Frantz D.E., Brekken R.A., Quinn A.M., Simeonov A., Easmon J., Martinez E.D. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat. Commun. 2013, 4:2035.
131. Hurych J., Chvapil M. Influence of chelating agents on the biosynthesis of collagen. Biochim. Biophys. Acta Gen. Subj. 1965, 97:361-363.
132. Hales N.J., Beattie J.F. Novel inhibitors of prolyl 4-hydroxylase. 5. The intriguing structure-activity relationships seen with 2,2'-bipyridine and its 5,5'-dicarboxylic acid derivatives. J. Med. Chem. 1993, 36:3853-3858.
133. Chang K.-H., King O.N.F., Tumber A., Woon E.C.Y., Heightman T.D., McDonough M.A., Schofield C.J., Rose N.R. Inhibition of histone demethylases by 4-carboxy-2,2'-bipyridyl compounds. ChemMedChem 2011, 6:759-764.
134. King O.N.F., Li X.S., Sakurai M., Kawamura A., Rose N.R., Ng S.S., Quinn A.M., Rai G., Mott B.T., Beswick P., Klose R.J., Oppermann U., Jadhav A., Heightman T.D., Maloney D.J., Schofield C.J., Simeonov A. Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors. PLoS ONE 2010, 5:e15535.
135. Liang Y., Vogel J.L., Arbuckle J.H., Rai G., Jadhav A., Simeonov A., Maloney D.J., Kristie T.M. Targeting the JMJD2 histone demethylases to epigenetically control herpesvirus infection and reactivation from latency. Sci. Transl. Med. 2013, 5. (167ra165, 111pp).
136. Geurink P.P., Prely L.M., van der Marel G.A., Bischoff R., Overkleeft H.S. Photoaffinity labeling in activity-based protein profiling. Activity-Based Protein Profiling 2012, vol. 324:85-113. S.A. Sieber (Ed.).
137. Rotili D., Altun M., Kawamura A., Wolf A., Fischer R., Leung Ivanhoe K.H., Mackeen Mukram M., Tian Y.-m., Ratcliffe Peter J., Mai A., Kessler Benedikt M., Schofield Christopher J. A photoreactive small-molecule probe for 2-oxoglutarate oxygenases. Chem. Biol. 2011, 18:642-654.
138. Bush J.T., Walport L.J., McGouran J.F., Leung I.K.H., Berridge G., van Berkel S.S., Basak A., Kessler B.M., Schofield C.J. The Ugi four-component reaction enables expedient synthesis and comparison of photoaffinity probes. Chem. Sci. 2013, 4:4115-4120.
139. Lohse B., Nielsen A.L., Kristensen J.B.L., Helgstrand C., Cloos P.A.C., Olsen L., Gajhede M., Clausen R.P., Kristensen J.L. Targeting histone lysine demethylases by truncating the histone3 tail to obtain selective substrate-based inhibitors. Angew. Chem. Int. Ed. 2011, 50:9100-9103.
140. Woon E.C.Y., Tumber A., Kawamura A., Hillringhaus L., Ge W., Rose N.R., Ma J.H.Y., Chan M.C., Walport L.J., Che K.H., Ng S.S., Marsden B.D., Oppermann U., McDonough M.A., Schofield C.J. Linking of 2-oxoglutarate and substrate binding sites enables potent and highly selective inhibition of JmjC histone demethylases. Angew. Chem. Int. Ed. 2012, 51:1631-1634.
141. Upadhyay A.K., Rotili D., Han J.W., Hu R., Chang Y., Labella D., Zhang X., Yoon Y.S., Mai A., Cheng X. An analog of BIX-01294 selectively inhibits a family of histone H3 lysine 9 Jumonji demethylases. J. Mol. Biol. 2012, 416:319-327.
142. Murray J.C., Cassell R.H., Pinnell S.R. Inhibition of lysyl hydroxylase by catechol analogs. Biochim. Biophys. Acta 1977, 481:63-70.
143. Wilson W.J., Poellinger L. The dietary flavonoid quercetin modulates HIF-1 alpha activity in endothelial cells. Biochem. Biophys. Res. Commun. 2002, 293:446-450.
144. Zhou Y.D., Kim Y.P., Li X.C., Baerson S.R., Agarwal A.K., Hodges T.W., Ferreira D., Nagle D.G. Hypoxia-inducible factor-1 activation by (-)-epicatechin gallate: potential adverse effects of cancer chemoprevention with high-dose green tea extracts. J. Nat. Prod. 2004, 67:2063-2069.
145. Sakurai M., Rose N.R., Schultz L., Quinn A.M., Jadhav A., Ng S.S., Oppermann U., Schofield C.J., Simeonov A. A miniaturized screen for inhibitors of Jumonji histone demethylases. Mol. BioSyst. 2010, 6:357-364.
146. Nielsen A.L., Kristensen L.H., Stephansen K.B., Kristensen J.B., Helgstrand C., Lees M., Cloos P., Helin K., Gajhede M., Olsen L. Identification of catechols as histone-lysine demethylase inhibitors. FEBS Lett. 2012, 586:1190-1194.
147. Sayegh J., Cao J., Zou M.R., Morales A., Blair L.P., Norcia M., Hoyer D., Tackett A.J., Merkel J.S., Yan Q. Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen. J. Biol. Chem. 2013, 288:9408-9417.
148. Kim S.-H., Kwon S.H., Park S.-H., Lee J.K., Bang H.-S., Nam S.-J., Kwon H.C., Shin J., Oh D.-C. Tripartin, a histone demethylase inhibitor from a bacterium associated with a dung beetle larva. Org. Lett. 2013, 15:1834-1837.
149. M.M.W.B.R.N.J. Labelle, C.A.G.N.R.R.W.O.O.X.D.S. Montalbetti, R.J.S.H.C.D.O.O.X.U.U. Mears, J.L.G.W.O.O.X.N.Y. Vile, D.M.F.A.M.E.V. Gelman, X.B.D.W.O.O.X.B.H. Gai, O.R.C.C.L.W.O.O.X.N.S. Barker, H.J.C.O.C.D.O.O.X.A.X. Deboves, S.P.T.C.W.O.O.X.B.B. East, T.L.t.D.K.C.Ø. Boesen, INHIBITORS OF HDME, in: O.M.V.D.K.C.N. Epitherapeutics Aps (Ed.), vol. DK2011/050280, WO, 2012.
150. M.M.W.B.R.N.J. Labelle, C.A.G.N.R.R.W.O.O.X.D.S. Montalbetti, R.J.S.H.C.D.O.O.X.U.U. Mears, INHIBITORS OF HDME, in: O.M.V.D.K.C.N. Epitherapeutics Aps (Ed.), vol. DK2011/050281, WO, 2012.
151. Wissmann M., Yin N., Mueller J.M., Greschik H., Fodor B.D., Jenuwein T., Vogler C., Schneider R., Guenther T., Buettner R., Metzger E., Schuele R. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat. Cell Biol. 2007, 9:347-353.
152. Rotili D., Tomassi S., Conte M., Benedetti R., Tortorici M., Ciossani G., Valente S., Marrocco B., Labella D., Novellino E., Mattevi A., Altucci L., Tumber A., Yapp C., King O.N.F., Hopkinson R.J., Kawamura A., Schofield C.J., Mai A. Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities. J. Med. Chem. 2014, 57:42-55.
153. Sedgwick B., Bates P.A., Paik J., Jacobs S.C., Lindahl T. Repair of alkylated DNA: recent advances. DNA Repair 2007, 6:429-442.
154. Yang M., Culhane J.C., Szewczuk L.M., Gocke C.B., Brautigam C.A., Tomchick D.R., Machius M., Cole P.A., Yu H. Structural basis of histone demethylation by LSD1 revealed by suicide inactivation. Nat. Struct. Mol. Biol. 2007, 14:535-539.
155. Fang R., Chen F., Dong Z., Hu D., Barbera A.J., Clark E.A., Fang J., Yang Y., Mei P., Rutenberg M., Li Z., Zhang Y., Xu Y., Yang H., Wang P., Simon M.D., Zhou Q., Li J., Marynick M.P., Li X., Lu H., Kaiser U.B., Kingston R.E., Xu Y., Shi Y.G. LSD2/KDM1B and its cofactor NPAC/GLYR1 endow a structural and molecular model for regulation of H3K4 demethylation. Mol. Cell 2013, 49:558-570.
156. Sengoku T., Yokoyama S. Structural basis for histone H3 Lys 27 demethylation by UTX/KDM6A. Genes Dev. 2011, 25:2266-2277.
157. Horton J.R., Upadhyay A.K., Qi H.H., Zhang X., Shi Y., Cheng X.-D. Enzymatic and structural insights for substrate specificity of a family of Jumonji histone lysine demethylases. Nat. Struct. Mol. Biol. 2010, 17:38-43.